Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer

AIM: The open‐label, nonrandomized, phase II APEC study enrolled 167 patients with RAS wild‐type (wt) metastatic colorectal cancer (mCRC) to investigate the safety and efficacy of first‐line, every‐2‐weeks cetuximab plus investigator's choice of FOLFIRI or FOLFOX in this patient population. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, Timothy, Shen, Lin, Ma, Brigette, Esser, Regina, Chen, Wenfeng, Gibbs, Peter, Lim, Robert, Cheng, Ann‐Lii
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852115/
https://www.ncbi.nlm.nih.gov/pubmed/31090260
http://dx.doi.org/10.1111/ajco.13154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852115/
https://www.ncbi.nlm.nih.gov/pubmed/31090260
http://dx.doi.org/10.1111/ajco.13154

Ejemplares similares